secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2024-07-25T23:59:59+00:00
Accession:  0001558370-24-010208
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 1.02, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech enters $50M Oaktree loan, repays prior $50M, extends maturity to 2027
--------------------------------------------------------------------------------

- Borrowed $35M initially under new $50M senior secured credit agreement with Oaktree; eligible for additional $15M at lenders' discretion.
- Interest rate of 3-month SOFR + 7.625% (2.50% floor, 5.75% cap); 30-month interest-only period, maturity July 25, 2027.
- Repaid and terminated existing $50M loan due August 2025; issued warrants to purchase 506,390 shares at $2.0735 per share.
- Covenants include minimum liquidity of $7M and Journey Medical minimum net sales of $50M trailing 12 months, tested quarterly.
- Company cites potential for up to three regulatory approvals on NDAs/BLAs in next 12 months and possible fourth BLA filing in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837024010208/0001558370-24-010208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837024010208/fbio-20240725x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-010208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer